Insmed Inc (INSM)vsPluri Inc. (PLUR)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
PLUR
Pluri Inc.
$3.33
+9.18%
HEALTHCARE · Cap: $34.09M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 45291% more annual revenue ($606.42M vs $1.34M). PLUR leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
PLUR
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
3.1% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : PLUR
PLUR has a balanced fundamental profile.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : PLUR
The primary concerns for PLUR are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while PLUR is a value play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
PLUR is growing revenue faster at 3.1% — sustainability is the question.
PLUR generates stronger free cash flow (-6M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Pluri Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Pluri Inc. is a cutting-edge biotechnology company specializing in regenerative medicine and immunotherapy, with a strong emphasis on developing innovative cell-based therapies. Utilizing its proprietary technology platform, Pluri aims to tackle significant unmet medical needs in oncology and degenerative diseases. The company boasts a robust pipeline and strategic partnerships that position it to improve patient outcomes and capitalize on growth opportunities within the dynamic healthcare landscape. By focusing on the transformative potential of human cells, Pluri is establishing itself as a key player in the biotechnology industry, committed to advancing novel therapeutic solutions.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?